



---

**ASX Announcement and Media Release**

**7 August 2018**

**SciGen Ltd**

---

**APPOINTMENT AND RESIGNATION OF COMPANY OFFICERS**

---

**1. Introduction**

The board of directors (the “**Board**” or the “**Directors**”) of SciGen Ltd (the “**Company**”) refers to the circular of the Company dated 19 July 2018 (the “**Circular**”) in relation to the voluntary conditional general offer (the “**Offer**”) by SAC Capital Private Limited, for and on behalf of Yifan International Pharmaceutical Co., Limited (the “**Offeror**”) for all the issued and paid-up ordinary shares in the capital of the Company (excluding treasury shares) (the “**Shares**”), other than those Shares already owned, controlled, or agreed to be acquired by the Offeror, but including Shares owned, controlled, or agreed to be acquired by parties acting or deemed to be acting in concert with the Offeror.

All capitalised terms used and not defined herein shall have the same meanings ascribed to them in the Circular, unless otherwise expressly stated or the context otherwise requires.

**2. Appointment of Company Officers**

The Board wishes to announce appointment of the following directors with effect from 7 August 2018:

- (a) Kang Yun and
- (b) Zou Jun

### 3. Resignation of Company Officers

The Board wishes to announce, as set out in Section 5.2 to Appendix B of the Circular, the resignation of the following directors with effect from 7 August 2018:

- (a) Marek Dziki;
- (b) Adam Tomasz Polonek;
- (c) Kenneth Gross;
- (d) Ju Bo Liu; and
- (e) Vaidyanathan Viswanath

(collectively, the “**Resigning Directors**”).

Further information of the Resigning Directors is contained in the final director’s interest notices of the Resigning Directors issued by the Company today.

The Board further wishes to announce that:

- (a) Marek Dziki has also resigned as the chief executive officer of the Company, and such resignation will take effect from 31 August 2018; and
- (b) Adam Tomasz Polonek has also resigned as (i) the secretary of the Company with effect from 7 August 2018, and (ii) the chief financial officer of the Company, and such resignation will take effect from 31 August 2018.

#### **4. Responsibility Statement**

The Directors (including those who have delegated detailed supervision of this announcement) have taken all reasonable care to ensure that the facts stated and opinions expressed in this announcement are fair and accurate, and that there are no other material facts not contained in this announcement, the omission of which would make any statement in this announcement misleading, and they jointly and severally accept responsibility accordingly. Where any information has been extracted or reproduced from published or otherwise publicly available sources, the sole responsibility of the Directors has been to ensure through reasonable enquiries that such information is accurately extracted from such sources or, as the case may be, reflected or reproduced in this announcement.

#### **BY ORDER OF THE BOARD**

For and on behalf of SciGen Ltd

**Yvonne Lim Lean Guat**

7 August 2018

## About SciGen Limited

SciGen Ltd (“SciGen”) is a biopharmaceutical company involved in sales and marketing of genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of endocrinology, paediatrics and oncology-care.

Its core product portfolio consists of biosimilar products, notably, recombinant human insulin and recombinant human growth hormone which have undergone substantial clinical development. SciGen has since built a diversified portfolio in recent years, comprising endocrinology, neurology, oncology-care products, paediatric supplements, orthopaedic injection therapy and a range of medical devices.

SciGen has acquired the rights to distribute and market biopharmaceutical and proprietary products under both exclusive and semi-exclusive licensing arrangements. SciGen’s current focus is in the Asia Pacific region which provides growth opportunities for its range of products.

SciGen currently maintains internal sales and marketing teams at its subsidiary offices, whilst venturing into distribution partnerships in other markets. Through joint collaboration with its partners, SciGen uses its extensive expertise in regulatory and clinical environments, to cater to a broader spectrum of market.

SciGen was established in 1988, as a Singapore biopharmaceutical company. SciGen is listed on the Australian Stock Exchange (ASX code : SIE). Its corporate headquarters is located in Singapore, with subsidiary offices in Australia, South Korea, China and a sales office in Philippines. Strategic distribution channels are present in Thailand, Hong Kong, Pakistan, Indonesia, Singapore, Bangladesh, Myanmar and Vietnam.

<b>For further information: Company - Investor Relations</b>	<b>Company</b>
Mr. Martin Naef SciGen (Australia) Pty Ltd +61 2 9485 1800 E-mail : <a href="mailto:MNaef@scigen.com.au">MNaef@scigen.com.au</a>	Ms. Yvonne Lim SciGen Ltd +65 6779 6638 E-mail : <a href="mailto:central@scigen.com.sg">central@scigen.com.sg</a>